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Background: Even after needle biopsy, intracystic tumors of the breast are challenging 
differentially diagnose preoperatively because of their nonspecific radiological 
characteristics and subtle cytological and histological appearance. The aim of this study 
is to investigate a novel diagnostic method, targeting genomic instability (GIN) in 
intracystic tumors of the breast, using tumor DNA from samples obtained by fine-needle 
aspiration biopsy (FNAB).  
Methods: Thirteen consecutive intracystic tumors of the breast, including five cancers 
and eight benign tumors, were studied. Three FNAB passages per tumor were used for 
array comparative genomic hybridization (aCGH) analysis to quantify GIN in each 
tumor. Tumor DNA from the main tumor, taken from formalin-fixed, paraffin-embedded 
(FFPE) blocks corresponding to FNAB samples, was also analyzed to compare 
cytogenetic profiles between these sample types.  
Results: After three FNAB passages, an average of 7.09 μg (0.24–25.0 μg) of DNA was 
obtained. The quality of the DNA and the aCGH data was excellent, as judged by the 
mean derivative log ratio spread (DLRSpread) of 0.22 (0.15–0.29). The cytogenetic 
profiles of paired FNAB and main tumor FFPE samples were highly similar, with an 
average concordance rate of 97.7% (81.2–100%). aCGH analysis from FNAB samples 
showed significantly more GIN in cancers than in benign tumors, with mean 
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frequencies of aberrant chromosomal regions of 17.5% and 0.34%, respectively 
(Wilcoxon’s rank sum test, P = 0.0016).  
Conclusions: Our novel diagnostic method, which targets GIN, can clearly distinguish 
cancers from benign tumors of breast intracystic lesions with minimal invasion, thereby 



















 Intracystic tumors of the breast include benign papillomas, which account for 
approximately 10% of benign breast tumors, as well as carcinomas in situ and 
carcinomas with invasion, which together account for less than 1% of malignant breast 
tumors [1–7]. Intracystic papillary carcinoma develops with a predilection for elderly 
women, who often present with a palpable mass and/or bloody nipple discharge [1, 2, 4]. 
Although this type of carcinoma has a good prognosis regardless of whether the tumor 
is diagnosed as in situ or invasive, there have been reports of metastasis to lymph nodes 
or distant organs [5, 8, 9]. 
In breast lesions, indication for surgery is usually determined by pathological 
diagnosis together with radiological findings. However, preoperative differential 
diagnosis between intracystic papillary carcinomas vs. papillomas is very challenging 
even after needle biopsy, because of their nonspecific radiological characteristics, and 
subtle cytological and histological appearance. Hence, surgical excisional biopsy is 
recommended in the clinical management of these lesions, especially when associated 
with risk factors for malignancy, such as age (≥ 50 years) and the presence of 
microcalcifications [6–8, 10]. A few papers have reported immunohistochemical 
techniques to be effective, but only in combination with other diagnostic techniques 
[11–13]. Although Shamonki et al. [14] recently reported that core needle biopsy (CNB) 
tissue samples consisting of at least seven cores, obtained by using a 12-gauge or larger 
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needle, had a negative predictive value for atypia/malignancy of 100 %, a less invasive 
diagnostic method is required. 
Meanwhile, genomic instability (GIN) is an important hallmark of cancer [15], 
which may be useful for distinguishing cancers from benign tumors. There are many 
reports indicating the presence of genomic alterations in intracystic papillary carcinoma 
of the breast [16–20]. We recently reported that genome-wide copy number aberrations 
could easily be detected by array comparative genomic hybridization (aCGH), which 
could then be used to quantify GIN, and that intracystic papillary carcinoma harbors 
significant GIN compared with intracystic papilloma [21]. However, a cytogenetic 
method for preoperative diagnosis of breast intracystic tumors has not been reported 
thus far.  
The aim of this study is to investigate a novel diagnostic method, targeting GIN 
in intracystic tumors of the breast, using tumor DNA from samples obtained by 









Materials and methods 
Tumor samples and pathological diagnosis 
Thirteen consecutive intracystic tumors of the breast were resected at Nagasaki 
University Hospital between August 2010 and March 2012, which included five cancers 
(four invasive ductal carcinoma and one non-invasive carcinoma) and eight benign 
tumors (five papilloma, two ductal adenoma and one sclerosing papilloma), were 
enrolled. Preoperative diagnosis by CNB and FNAB, and postoperative final diagnosis 
was independently determined by two pathologists (Table 1).  
 All experimental procedures for this study were approved by the Committee for 
Ethical Issues on the Human Genome and Gene Analysis of Nagasaki University 
(#08073134) and all patients provided informed consent for voluntary participation. 
 
Sampling and tumor DNA extraction 
An experienced surgeon performed FNABs using a 22-gauge aspiration needle. 
Three FNAB passages per tumor were performed. All samples were suspended in 380 
μL PBS and tumor DNA was immediately extracted using the QIAmp DNA Mini Kit 
(Qiagen, Dusseldorf, Germany) following the manufacturer’s instructions. 
Formalin-fixed, paraffin-embedded (FFPE) blocks of the resected tumors were 
processed to extract tumor DNA, as previously reported [21–23]. Briefly, samples were 
macrodissected using 10–20 10-μm-thick sections. Tumor tissue areas containing more 
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than 70% tumor cells, as identified by a guide slide stained with hematoxylin, were 
selected and manually dissected using surgical scalpels. Paraffin removal was 
performed in 80% xylene after which samples were washed twice with absolute ethanol. 
Deparaffinized tissue pieces were spun down, after which the dried up pellet was 
resuspended in 360 μL buffer ATL and incubated at 95 °C for 15 min. Samples were 
allowed to cool down to room temperature and subsequently digested with proteinase K 
for 3 days at 56 °C in a rotation oven with periodic mixing and fresh addition of 
proteinase K every 24 h. DNA was extracted using the QIAmp DNA Mini Kit according 
to the manufacturer’s instructions with some modifications. Briefly, 400 μL buffer AL 
was added to the sample, which was then incubated at 70 °C for 10 min followed by the 
addition of 400 μL absolute ethanol and mixing by vortex. The sample solution was 
applied to the spin column followed by centrifugation for 1 min at 8000 ×g. The spin 
column was washed twice with 500 μL buffer AW1 by centrifugation at 8000 ×g for 1 
min and washed with 80% ethanol by centrifugation at 14,000 ×g for 3 min. Finally, the 
DNA was eluted with 55 μL nuclease free water. 
DNA was quantitated using the ratio of absorbance at 260 and 280 nm 
(A260/A280), and 260 and 230 nm (A260/A230) on a NanoDrop ND-2000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE). The double-strand DNA 
concentration in each sample was quantitated on a Qubit fluorometer with the Qubit 
dsDNA HS Assay Kit (Life Technologies, Carlsbad, CA) following the manufacturer’s 
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instructions as a quality indicator of DNA for aCGH analysis [25].  
 
aCGH analysis 
 The Genomic DNA ULS Labeling Kit (Agilent Technologies, Palo Alto, CA) 
was used to chemically label 500 ng of DNA from each sample and 250 ng of reference 
female genomic DNA (Promega, Madison, WI) with Cy5 or Cy3 dye, respectively, for 
30 min at 85 °C, followed by purification using Agilent-KREApure™ columns. The 
amount of input DNA was determined on a Qubit fluorometer using the Qubit dsDNA 
HS Assay Kit. The degree of Cy5 labeling (absorbance at 650 nm) was calculated using 
a NanoDrop ND-2000 spectrophotometer. Purified, labeled samples were then 
combined and mixed with human Cot-1 DNA (Invitrogen, Carlsbad, CA), Agilent 10× 
Blocking Agent and Agilent 2× Hybridization Solution. Prior to array hybridization, 
hybridization mixtures were denatured at 95 °C for 3 min and incubated at 37 °C for 30 
min. Agilent CGHblock was added and samples were hybridized to SurePrint G3 
Human CGH 8×60K Microarrays, which contain eight identical arrays consisting of 
~63,000 in situ synthesized 60-mer oligonucleotide probes that span coding and 
noncoding sequences with an average spatial resolution of ~54 kb. Hybridization was 
carried out at 65 °C for 40 h before washing with Agilent Oligo aCGH Wash Buffer 1 at 
room temperature for 5 min, followed by washing with Agilent Oligo aCGH Wash 
Buffer 2 at 37 °C for 1 min. Scanning and image analysis were done on an Agilent DNA 
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Microarray Scanner. Agilent Feature Extraction Software (version 9.5) was used for 
data extraction from raw microarray image files. Agilent Genomic Workbench (version 
5.0) was used to visualize, detect and analyze chromosomal patterns using the 
Aberration Detection Method 2 (ADM-2) algorithm with the default settings. The 
derivative log ratio spread (DLRSpread) of each sample, which estimates the log ratio 
noise by calculating the spread of log ratio differences between consecutive probes 
along all chromosomes, and is an indicator of the quality of aCGH analysis, was also 
calculated using Agilent Genomic Workbench (version 5.0). A copy number gain or loss 
was defined as a log2 ratio > 0.25 or < -0.25, respectively. 
 
Statistical analysis 
The total rate of a copy number altered (CNA) region, defined as the sum of 
each segment gained or lost and divided by 2,829 Mb, which is the total Mb in the 
genome excluding heterochromatic, centromeric and telomeric regions not covered by 
probes, was used as an indicator of GIN. Wilcoxon’s rank sum test was performed to 
compare the rate of a CNA region between cancer and benign tumor samples.  
To compare the cytogenetic profiles of FNAB samples and their corresponding 
FFPE blocks, we used the concordance rate (CR), which was defined as the ratio of the 
copy number length of a given segment within pairs. 




http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html; Kanda, 2012), 
which is a graphical user interface for R (The R Foundation for Statistical Computing, 
Vienna, Austria, version 2.13.0) [24]. More precisely, it is a modified version of R 
commander (version 1.6-3) that was designed to add statistical functions frequently 
used in biostatistics. The results were considered statistically significant when the 


















Preoperative FNAB was conducted in 12 of 13 cases, of which four cases 
(33.3 %) could be diagnosed as malignant, preoperatively. In four of 13 cases, 
preoperative CNB was conducted, of which three cases (75%) could be diagnosed as 
malignant, preoperatively. Notably, one case of ductal adenoma (case 3) was diagnosed 
as malignant by FNAB and as undetermined by CNB.  
After three FNAB passages, sufficient amounts of DNA were obtained with an 
average of 7.09 μg (0.24–25.0 μg). The mean ratio of double-strand to total DNA 
(dsDNA ratio) of the samples, which is a DNA quality indicator for aCGH analysis, 
with a higher ratio indicating better quality [25], was 0.70 (0.31–0.95). The quality of 
the aCGH data were excellent, with a DLRSpread of less than 0.30, with mean of 0.22 
(0.15–0.29) for all cases (Table 1).  
The aCGH results using DNA from paired FNAB and main tumor FFPE 
samples, produced highly similar cytogenetic profiles within pairs, with an average 
concordance rate, defined as the ratio of copy number length of a given segment within 
pairs, of 97.7% (81.2–100%) (Table 1, Figure 1).  
aCGH analysis of FNAB samples showed that cancers harbored significantly more GIN 
than benign tumors, with mean frequencies of aberrant chromosomal regions of 17.5% 
and 0.34%, respectively (Wilcoxon’s rank sum test, P = 0.0016) (Figure 1, Figure 2). In 
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five malignant tumors, four cases (80%) showed 16q loss and three cases (60%) showed 























 Preoperative differential diagnosis of intracystic tumors of the breast is 
challenging because of their nonspecific radiological characteristics, and subtle 
cytological and histological appearance. Only 33 % and 75 % of intracystic cancers of 
the breast were diagnosed as malignant by FNAB and CNB, respectively in this study, 
which is comparable to the other reports [6]. In the present study, we therefore used 
intra-cystic tumors of the breast to validate a new diagnostic method targeting GIN in 
intracystic tumors of the breast, using tumor DNA from samples obtained by FNAB. 
 By performing three passages of FNAB, sufficient amounts and quality of 
DNA were obtained for aCGH analysis, which requires only 250 ng of tumor DNA per 
sample, which resulted in sufficient aCGH quality with a mean DLRSpread of 0.22. In 
this study, we did not assess the purity of tumor cells. However, Symmans et al. [26] 
reported that compared with CNB, FNAB yields a similar quality of tumor RNA, with 
less contamination with normal stromal cells. Considering the clear cytogenetic profile 
of our cancer samples, the purity of tumor cells was assumed to be acceptable.  
 The cytogenetic profiles of paired FNAB and main tumor FFPE samples were 
highly similar, with an average concordance rate of 97.7 %. Although intra-tumoral 
heterogeneity may result in discordant cytogenetic profiles, this minor effect may be 
considered negligible when distinguishing malignant from benign samples by our 
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method. Moreover, cytogenetic profiles of five cancer cases showed 16q loss and 1q 
gain as the most frequently altered region, which is a typical cytogenetic profile of 
papillary breast carcinomas, as reported previously [16–20].  
The results of aCGH analysis from FNAB samples showed that cancers 
harbored significantly more GIN than benign tumors, with mean frequencies of aberrant 
chromosomal regions of 17.5% and 0.34%, respectively, which was concordant with our 
data published previously using FFPE samples of breast intracystic tumors [21]. If we 
endorse 3 % of frequencies of aberrant chromosomal regions as a cut-off value to 
distinguish malignant from benign samples, our data set was completely segregated. 
However, to decide on an accurate cut-off value, prospective analysis of additional 
samples with receiver operating characteristic (ROC) analysis is required.  
In conclusion, our novel diagnostic method, which targets GIN, can clearly 
distinguish cancers from benign tumors of breast intracystic lesions with minimum 
invasion, thereby avoiding the need for surgical excisional biopsy. This methodology 
may be extrapolated to other breast lesions where it is difficult to distinguish malignant 
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FIGURE LEGENDS 
Figure 1. Graphic display of whole genome copy number changes in carcinoma 
samples using FNAB (a), FFPE samples of the main tumor (b) and benign lesion 
samples using FNAB (c). 
Log2 ratio values for all oligonucleotide probes are plotted as a function of their 
chromosomal position. Aberration calls identified by the ADM-2 algorithm are shown 
as upper and lower horizontal bars, respectively. The number of each column represents 
each chromosome. 
Figure 2. The mean ratio of copy number alteration (CNA) was compared between 
carcinomas and benign lesions. 
The central rectangle spans the first to the third quartile. The segment inside the 
rectangle indicates the median and "whiskers" above and below the box indicate the 
locations of the minimum and maximum. 
Figure 3. Graphic display of whole genome aberrations in intracystic carcinoma of 
the breast. 
The panels to the right of each chromosome show the frequency of gains (red bars) and 
21 
losses (green bars), each ranging from 0 % to 100 %. 















(a). FNAB-aCGH, carcinoma (n=5) 
(b). FFPE-aCGH, carcinoma (n=5)































Table 1. Characteristics of cases in the present study. 
Case Age Final diagnosis Cytology CNB Total amount 
of DNA (μg) 
dsDNA 
ratio 
Ratio of CNA 
region (%) 
Number of CNA 
region 
Overlap of FNAB-aCGH 
and FFPE-aGGH (%) 
1 58 IDC V Malignancy 8.6 0.74 3.57 20 99.7 
2 40 Papilloma III NA 1.8 0.76 0.07 3 99.9 
3 63 Ductal adenoma V Indeterminate 4.1 0.81 0.004 1 100 
4 41 Papilloma III NA 5.9 0.74 0.05 2 99.9 
5 67 Sclerosing 
Papilloma 
III NA 0.24 0.48 0.17 10 NA 
6 57 Papilloma III NA 25.0 0.93 0.007 1 100 
7 74 Papilloma III NA 0.71 0.57 1.90 42 98.1 
8 75 IDC V NA 18.0 0.88 65.1 79 81.2 
9 49 IDC III NA 16.1 0.95 9.12 16 99.1 
10 68 Papilloma NA NA 1.21 0.63 0.36 15 99.7 
11 67 IDC V Malignancy 5.81 0.51 6.20 15 98.8 
12 67 DCIS V Malignancy 4.34 0.79 3.65 4 96.3 
13 89 Ductal adenoma III NA 0.41 0.31 0.15 17 99.8 
IDC: invasive ductal carcinoma, CNB: core needle biopsy, dsDNA: double-stranded DNA, CNA: copy number alteration, FNAB: fine needle aspiration 
biopsy, aCGH: array-comparative genomic hybridization, FFPE: formalin-fixed paraffin-embedded, NA: not analyzed.  
